🇺🇸

IPO Capital Markets

· daily

US IPO Pipeline SEC S-1 Filings — June 12, 2026

The IPO pipeline is heavily weighted towards SPACs and distressed companies raising emergency capital, signaling a bifurcated market. Three blank-check companies (Southern Cross, Ares, Thunder Bridge) are seeking a combined $550M+ to acquire targets, while Splash Beverage and Lantern Pharma are in dire financial straits, with Splash facing imminent delisting and Lantern having a going concern qualification and only 9 months of cash. The period-over-period data reveals stark contrasts: bioAffinity Technologies saw a concerning 34% revenue decline from FY2024 to FY2025, while Rome Wildlife's share price collapsed 38.8% in six weeks as its merger valuation becomes increasingly unfavorable. Insider activity is absent from most filings, a red flag for investor sentiment, but Narragansett Bancorp's IPO stands out as a traditional community bank offering with a structured use of proceeds. The most critical development is the proposed NYSE American rule change that could trigger immediate delisting for micro-cap issuers, threatening Splash and potentially other distressed companies. The market is showing a clear preference for high-quality, asset-light SPAC sponsors (Ares, Thunder Bridge) over distressed operating companies.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 11, 2026

The IPO pipeline digest for June 11, 2026, reveals a bifurcated market: two blank-check companies (Pelican Acquisition II Corp and Viking Acquisition Corp. II) are seeking a combined $275M+ to target technology and unspecified businesses, signaling sustained SPAC appetite despite regulatory scrutiny, while two operating companies (FingerMotion, Inc. and Cardiff Lexington Corp) are pursuing dilutive at-the-market (ATM) and convertible note financings to shore up liquidity. FingerMotion’s S-1 update reveals a critical market cap drop below $75M, forcing reliance on SEC guidance to sell up to $50M in stock, and a recent $5M convertible note at a steep 14% OID, indicating acute capital needs. Cardiff Lexington’s filing for up to 50M shares resale under a $75M purchase agreement (with a $0.20 floor) highlights extreme dilution risk and management’s broad discretion over proceeds. No period-over-period comparisons or insider trading data were available in these initial filings, but forward-looking capital allocation plans and transaction terms provide actionable signals. The overarching theme is capital urgency: SPACs chase growth targets while distressed issuers tap equity-linked instruments, creating both dilution risks for existing holders and potential alpha for event-driven investors.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 10, 2026

The IPO pipeline for June 10, 2026, is characterized by a mix of early-stage blank check companies, crypto-backed acquisitions, and traditional service firms, with a notable absence of high-growth tech unicorns. Period-over-period data reveals divergent revenue trends: OFA Group's Design and Fit-Out Services drove growth, but its Application Services segment declined in the latest fiscal year, while Swarmer and American Ventures have no operational revenue to compare. Forward-looking statements are sparse, with only ZeroStack's S-4 providing a specific transaction valuation ($107.4M for 0G tokens), signaling a shift toward crypto-based deal structures. Insider trading activity is absent across all filings, limiting management conviction signals, but capital allocation insights show American Ventures' redemption restrictions (15% threshold) could deter large investors. The most critical development is ZeroStack's complex crypto acquisition, which carries high execution risk given its early-stage status (21 employees) and lack of disclosed revenue. Portfolio-level themes include a reliance on related-party transactions (OFA Group's bridge loan conversion) and regulatory scrutiny of blank check companies (American Ventures). Overall, the pipeline suggests a cautious market environment with limited high-quality issuers, favoring investors who can stomach speculative assets and complex deal structures.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 09, 2026

The IPO pipeline filings on June 9, 2026, reveal a market dominated by distressed companies and secondary offerings rather than traditional IPOs. Five of seven filings are resale registrations (S-1) or exchange offers (S-4) that provide no primary capital to issuers, signaling a lack of fresh equity issuance. Coeptis Therapeutics and SOBR Safe face severe going concern risks with accumulated deficits of $113.9M and $15.6M, respectively, while Wolfspeed emerges from Chapter 11 bankruptcy. Onconetix and Starfighters Space show mixed signals with growing losses but potential catalysts (Proclarix test, space contracts). Broadcom's two exchange offers are routine registration rights fulfillments, generating no proceeds. The overall theme is caution: companies are raising capital through secondary sales rather than primary offerings, and several face existential financial challenges.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 08, 2026

The IPO pipeline on June 8, 2026, is dominated by three new SPAC filings (AParadise II, Research Alliance Corp IV, and Cartesian Growth Corp IV) collectively seeking to raise $635 million, signaling a resurgence in blank-check activity despite a challenging regulatory environment. Among the three follow-on filings, AIM ImmunoTech, HCW Biologics, and Agape ATP Corp all exhibit mixed sentiment due to operational risks, Nasdaq compliance issues, and uncertain capital structures. Period-over-period data reveals Agape ATP Corp narrowing its net loss by 52% YoY in Q1 2026, while AIM ImmunoTech and HCW Biologics show no revenue from approved products, relying on warrant exercises for potential cash. Insider activity is absent across all filings, but forward-looking statements highlight key catalysts: AIM's planned Phase 3 pancreatic cancer trial with Thermo Fisher, HCW's Phase 1 alopecia areata data, and Agape's unresolved $24.1M investment deposit. The most critical developments are the SPACs' lack of identified targets, which creates binary risk, and the biotech firms' reliance on regulatory approvals and Nasdaq compliance deadlines. Portfolio-level patterns include a concentration of high-risk, pre-revenue companies in the follow-on space and a return of large SPAC IPOs targeting $250M+ raises.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 05, 2026

The IPO pipeline is active with five new S-1 filings on June 5, 2026, spanning digital assets, mining, quantum computing, and retail, alongside two follow-on filings for debt exchange and ETF creation. A key theme is the prevalence of 'controlled company' structures post-IPO, with ITG, Sinda Ltd., and SharonAI all featuring dual-class shares or majority control by existing owners, limiting minority shareholder influence. Financially, Banzai International shows a mixed picture with 18.4% revenue growth but a net loss that more than doubled to $12.7M in Q1 2026, highlighting the cash-burn risks typical of pre-profit IPOs. The Grayscale Canton ETF and SharonAI filings underscore the continued institutional push into digital assets despite extreme volatility. A major red flag is Zapata Quantum's S-1, filed despite ceasing operations in 2024, with a low OTC stock price and no clear path to uplisting, suggesting a distressed or speculative offering. Overall, the pipeline is diverse but carries significant execution and governance risks, with only DICK'S Sporting Goods offering a low-risk, neutral debt exchange.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 04, 2026

The IPO pipeline on June 4, 2026, shows a bifurcated market: two blank-check companies (Watu Metals and Meridian3 Industrials) are raising a combined $275.5M in SPAC IPOs, signaling continued appetite for special-purpose acquisition vehicles despite regulatory scrutiny, while two S-4 filings (Hanover Bancorp and Helix Energy) indicate ongoing M&A and capital restructuring activity. The most critical development is Nukkleus Inc.'s S-1 filing, which reveals a deeply troubled company with negative working capital of $69M, a net operating loss of $3.8M in Q1 2026, and substantial doubt about its ability to continue as a going concern—yet management claims a $7.0M cash balance and an ELOC with $6.6M monthly drawdown capacity alleviate that doubt, creating a high-risk/high-reward scenario. Period-over-period comparisons are limited as most filers are newly formed or in early stages, but Nukkleus's deteriorating financials (negative working capital, operating losses) stand out as a red flag. The lack of revenue growth or margin trends across the cohort reflects the early-stage nature of these filings, but the concentration of SPACs (2 of 5 filings) suggests a resurgence in blank-check activity. Insider activity is minimal, with no notable insider transactions reported, but Nukkleus's CEO Menachem Shalom's multiple CEO roles (Star 26, Motomova, Hold Me) raise governance concerns. Forward-looking data is sparse, but the 12-month deadline for Watu Metals to complete a business combination creates a catalyst calendar for SPAC investors.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 03, 2026

The IPO pipeline is dominated by SPAC filings (Gores Holdings XI, Norient Acquisition) and business combinations (Banner Corp, Versa Bancorp), with NEXTNRG as a direct listing for a cash-strapped company. Key themes include aggressive SPAC structures with redemption risks, reliance on Canadian real estate (Versa Bancorp), and severe cash constraints (NEXTNRG). No period-over-period comparisons or insider activity were available in the enriched data, limiting trend analysis. The most critical development is NEXTNRG's cash runway ending July 31, 2026, signaling imminent dilution or failure. Investors should focus on SPAC redemption thresholds and target quality, while monitoring Versa Bancorp's exposure to Canadian housing. Overall, the pipeline skews risky with limited upside catalysts.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 02, 2026

The IPO pipeline on June 2, 2026, was dominated by six filings spanning digital infrastructure, lithium mining, unsecured debt, metals, and micro-cap tech. While overall sentiment skews negative (three filings bearish, two neutral, one mixed), there is no outright bullish filing, signaling cautious market conditions for new issuances. Revenue growth trends are divergent: **BlockchAIn Digital Infrastructure** grew revenue 5.6x YoY (from $0.9M to $5.0M) but losses widened 5x, while other filers lack disclosed period comparisons. Forward-looking statements across filings are uniformly cautious, with no upward guidance revisions. Insider trading activity was notably absent across all filings, suggesting limited management conviction at current valuation levels. The most critical development is the $500M SPAC merger-backed listing of **US Elemental Inc.** on Nasdaq, which introduces a pure-play lithium exposure. The continuous unsecured note offering by **Phoenix Energy One** ($100M, no listing, no trading market) presents the highest liquidity risk. Capital allocation data is sparse, with no dividends, buybacks, or splits disclosed. The lack of financial ratios and operational metrics in most filings limits deep cross-portfolio trend analysis, but the concentrated losses in the digital infrastructure space and the illiquid debt offering warrant immediate investor attention.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 01, 2026

The IPO pipeline for June 1, 2026, features two filings with mixed sentiment, reflecting divergent capital market strategies: a merger-driven S-4 from Global Net Lease (GNL) and a traditional IPO S-1 from AEVEX Corp. Period-over-period data reveals a stark contrast in financial health—AEVEX shows revenue growth of 11.1% YoY but a 14.3% decline in net income, signaling margin compression and operational inefficiencies, while GNL’s merger implies a fixed valuation range ($17.83–$18.82 per Modiv share) without market price adjustments, reducing volatility but exposing dilution risks. Key developments include GNL’s merger closing deadline of February 3, 2027, and a potential $10–$15 million termination fee, alongside AEVEX’s non-recurring $0.5 million legal settlement. Portfolio-level patterns highlight a theme of growth at the expense of profitability, with both filings lacking insider trading activity and forward-looking guidance, limiting near-term catalyst visibility. The most critical market implication is the need to monitor merger execution risks and AEVEX’s ability to reverse net income declines post-IPO.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 29, 2026

The IPO pipeline digest for May 29, 2026 reveals a bifurcated market: two blank-check companies (SPACs) are raising $200M and $100M despite no identified targets, signaling persistent appetite for speculative vehicles, while de-SPAC and small-cap issuers show significant distress. Kodiak AI's S-1, filed post-business combination, highlights serious liquidity constraints with $10M of SAFE loans unconverted and no draw on a $20M facility, yet it secured $205M in new equity, suggesting a high-risk/high-reward profile. BullFrog AI embodies micro-cap peril—a going concern with Nasdaq non-compliance on bid price and a pending August 10 deadline—offset only by a one-year feasibility agreement with a large pharma. PEBO's S-4 merger, with a fixed exchange ratio and limited OTC market for the target, carries integration risk but may appeal to value-oriented investors. Across the five filings, there is a clear absence of insider buying signals (none reported), heavy reliance on forward-looking feasibility and earn-outs, and a dominant theme of capital-constrained entities using registered offerings to stabilize or exit. No period-over-period revenue or margin comparisons were available in these pre-revenue or shell-company filings, limiting trend analysis but underscoring the speculative nature of this pipeline.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 28, 2026

The IPO pipeline on May 28, 2026, presents a bifurcated landscape: two legitimate growth-oriented filings (Entrata and GridAI) alongside two speculative or distressed situations (Youmi and the Peach State merger). Entrata's S-1 signals a high-profile tech IPO with complex compensation structures tied to majority owner returns, while GridAI's registration for warrant resale reflects a post-reverse-merger transformation into AI infrastructure with zero revenue from its new platform. The Peach State merger (UCB S-4) introduces a traditional banking consolidation with a fixed exchange ratio and regulatory hurdles. Period-over-period comparisons are limited as most filers lack historical financial data, but GridAI's shift from biopharma to AI-data center energy optimization represents a dramatic pivot. Insider activity is absent across filings, but the lack of proceeds to issuing companies (GridAI, Youmi) raises capital structure concerns. The overall sentiment is cautious, with materiality scores uniformly high (8/10) due to the transformative nature of these events.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 27, 2026

The IPO pipeline is dominated by three distinct capital-raising events and one transformative exchange offer, signaling a bifurcated market where distressed companies seek emergency funding while growth platforms execute strategic acquisitions. LiqTech International's S-1 reveals acute cash needs, with $1.1M in high-discount notes issued just two months before the offering, while urban-gro's S-1 marks a radical pivot from a discontinued agriculture business to a cricket media platform, creating valuation uncertainty. SoundHound AI's S-4 for LivePerson acquisition introduces a collar mechanism that caps stock consideration, reflecting market volatility concerns, while HBT Financial's exchange offer is a routine debt management move. Period-over-period data from the enriched filings shows no direct revenue or margin trends across the set, but insider activity is notably absent, and forward-looking guidance is limited to deal timelines. The most critical development is urban-gro's complete business transformation, which carries a materiality score of 10/10 and demands immediate investor attention.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 26, 2026

The IPO pipeline is active with 9 filings on May 26, 2026, spanning diverse sectors including specialty chemicals (VARSAL TECH), biotech (Kardigan, GeoVax), solar construction (SOLV Energy), power solutions (Forgent), SPAC (Crestone), quantum computing via SPAC merger (SeeQC), space/defense (Firefly Aerospace), and a UK-based company (DPC Holdings). A key theme is the prevalence of mixed sentiment, with most issuers showing significant financial challenges: widening net losses (Kardigan's Q1 2026 loss tripled YoY), declining government revenue (GeoVax's Q1 2026 contract revenue dropped to $0), and material weaknesses in internal controls (VARSAL TECH). Insider activity is notably absent across all filings, suggesting limited management conviction at current valuations. Capital allocation is focused on R&D and expansion, with no dividends or buybacks. The most critical development is SeeQC's SPAC merger with a $65M PIPE, but execution risk exists as only 48.8% of warrant holders have consented (needs 65%). Sector themes reveal a bifurcation: capital-intensive industrial IPOs (VARSAL, SOLV, Forgent) carry high debt and customer concentration, while biotech IPOs (Kardigan, GeoVax) show escalating cash burn with no product revenue. The absence of insider buying and prevalence of net losses suggest investors should be highly selective, focusing on companies with clear catalysts like GeoVax's Phase 3 trial or Firefly's NASA contract.

9 high priority 9 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 22, 2026

Today's IPO pipeline digest covers 7 S-1 filings, revealing a market bifurcated between high-risk, capital-intensive growth stories and traditional blank-check vehicles. The most critical development is the surge in SPAC activity, with two new $450M+ offerings (Cantor Equity Partners VII and Snow Rothschild Acquisition Corp.) signaling renewed sponsor confidence, though both carry extreme dilution risks for public shareholders. On the operational front, iQSTEL and Flux Power highlight a troubling pattern: both are going public with significant accumulated deficits and going-concern qualifications, relying on dilutive equity lines or debt restructurings for survival. Nuwellis stands out as the highest-risk filing, facing a proposed Nasdaq rule change that could force delisting, while Hyperliquid's unique structure (reverse recapitalization with HYPE token exposure) introduces novel crypto-accounting risks. Period-over-period trends are sparse in these initial filings, but the common thread is that 5 of 7 companies are emerging growth companies electing reduced disclosure, masking true financial health. The most actionable insight is the 60-month equity line at iQSTEL, which provides a $50M capital backstop but at a guaranteed 6% discount to market, creating a predictable dilution overhang that active traders can exploit.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 21, 2026

The IPO pipeline on May 21, 2026, reveals a bifurcated market: two distressed biotech resale registrations (Brainstorm Cell Therapeutics and Azitra) signal severe capital needs and shareholder dilution, while one blank-check company (BTECH Corp) launches a $200 million SPAC targeting the oil and gas and energy transition sectors. Period-over-period data shows Brainstorm's net losses flat at $22.589 million for two consecutive years, indicating no operational progress, while Azitra's assets of only $5.0 million and a going concern opinion underscore acute financial fragility. In contrast, BTECH's SPAC structure offers a clean slate with no operating history, but immediate dilution from sponsor shares at $0.003 per share is a structural risk. The absence of insider trading activity across all three filings suggests management is not signaling conviction through personal investment. The overarching theme is capital desperation in biotech versus speculative SPAC capital formation in energy, with all three filings carrying high dilution risk for investors.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 20, 2026

The IPO pipeline on May 20, 2026, is dominated by high-profile, high-growth names, including SpaceX and Medline, alongside a traditional SPAC (FutureCorp) and a nuclear energy play (Deep Fission). A key theme is the prevalence of secondary offerings and insider monetization, most notably Medline's filing by pre-IPO owners (Blackstone, Carlyle, H&F) and SpaceX's dual-class structure ensuring Elon Musk's control. The Skyworks/Qorvo S-4 filing, while not an IPO, signals significant M&A activity in the semiconductor sector, with a $1.55B debt exchange offer. Period-over-period data reveals strong revenue growth trajectories, with Medline boasting an 18% CAGR since inception and Picard Medical showing a 15% YoY revenue increase. However, dilution risks are acute: FutureCorp's sponsor acquired founder shares at $0.004 vs. the $10.00 IPO price, and Medline's secondary offering could pressure the stock. The overall sentiment is mixed, balancing high-growth opportunities against significant dilution and governance risks.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 19, 2026

The IPO pipeline on May 19, 2026, presents a highly polarized landscape, ranging from a development-stage interior design company with a going concern warning to a biotech firm with a $75M strategic investment from Regeneron. The most significant period-over-period trend is the escalating cash burn at Parabilis Medicines, where net losses widened 24% YoY to $145.9M, contrasting sharply with the nascent stage of Lawaken Group, whose CEO compensation surged 531% YoY to $1.85M despite a lack of employee benefits. A notable capital allocation pattern emerges with JAB Acquisition Corp I raising $150M in a SPAC IPO, signaling continued appetite for blank-check vehicles targeting tech, healthcare, and logistics. The absence of insider trading data across all filings is a critical gap, limiting conviction signals. The most actionable development is Regeneron's $75M private placement in Parabilis at a 10% discount to the IPO price, which provides a strong validation signal but also creates a potential overhang. The pipeline is dominated by high-risk, early-stage issuers, with 3 of 5 filings showing negative or going-concern sentiment, suggesting a cautious market reception ahead.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 14, 2026

The IPO Pipeline stream shows a surge in SPAC-related activity with 4/6 filings being S-4 registrations for business combinations (Exascale Labs, Puget Energy, McCarthy Finney, Electra Vehicles), alongside two S-1 filings for new SPAC IPOs and follow-ons (Yorkville International, Vivakor), signaling robust de-SPAC and blank-check company momentum on May 14, 2026. Positive sentiment dominates high-materiality deals like Yorkville's $200M IPO and Exascale's merger with 94% voting power retention, while neutral tones prevail in energy-focused filings with multi-period XBRL data (Puget FY2023-2026, Vivakor FY2024-2025). Period-over-period trends are nascent but highlight operational expansions via acquisitions (Vivakor's Endeavor Crude Oct 2024) and divestitures (Jul 2025), with no explicit revenue/margin declines noted across filings. Key implications include potential market re-entry for tech/AI (Electra at $250M valuation) and energy firms via SPACs, with dilution risks from warrants/redemptions and insider-held founder shares. Portfolio-level pattern: 67% of filings tied to SPACs, favoring emerging markets/tech over traditional IPOs, positioning investors for post-effectiveness catalysts.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 13, 2026

The IPO Pipeline stream shows two key filings on May 13, 2026: USA Rare Earth (USAR) S-4 for a strategic merger with Texas Mineral Resources Corp. (TMRC), carrying positive sentiment and high materiality (9/10), and Nauticus Robotics S-1 for resale of up to 103.7M shares under a $250M facility, mixed sentiment (8/10 materiality) amid dilution risks. No direct YoY/QoQ financial trends available in these registration statements, but USAR's merger implies consolidation potential in rare earths with a fixed 3.82M share pool exchange. Nauticus demonstrates recent positive trend in Nasdaq compliance (regained Dec 19, 2025 after Oct 2025 deficiencies) but faces ongoing monitoring. Critical development: USAR-TMRC Q3 2026 closing catalyst post TMRC vote, offering de-SPAC-like path to public markets for TMRC. Portfolio-level pattern: 1/2 filings (50%) leverage mergers/S-1s for capital access/public listing in emerging sectors, highlighting small-cap reliance on dilutive/strategic structures amid regulatory hurdles.

2 high priority 2 total filings